ROOP LAL, M.D.; PETER D. CHAPMAN, M.D.; GERALD V. NACCARELLI, M.D.; KENNETH B. SCHECHTMAN, Ph.D.; ROBERT L RINKENBERGER, M.D.; PAUL J. TROUP, M.D.; SUNG SOON KIM, M.D.; ANNE H. DOUGHERTY, M.D.; RODOLPHE RUFFY, M.D.
Thirty-two patients received flecainide acetate for nonsustained ventricular tachycardia after having had unsuccessful treatment with a mean of four antiarrhythmic drugs. The mean left ventricular ejection fraction was 41% in 27. Thirty-one patients had organic heart disease, and 22 patients had arrhythmia-related symptoms. Total suppression of ventricular tachycardia occurred in 22 patients. Thirty patients were discharged from the hospital receiving flecainide at a mean (± SD) dosage of 315 ± 76 mg/d and 26 of these patients attained a mean trough plasma drug level of 567 ± 254 ng/mL. One patient had proarrhythmia and 3 had worsening of heart failure. Twenty-two patients remained in the trial for a mean follow-up of 13 ± 7 months. Five patients died (1 suddenly) during the follow-up period. Our data indicate that flecainide suppresses refractory nonsustained ventricular tachycardia in 69% of patients who have organic heart disease. Serious adverse effects were minimized by initiation of treatment in the hospital and careful surveillance of electrocardiograms and plasma drug levels.
LAL R, CHAPMAN PD, NACCARELLI GV, SCHECHTMAN KB, RINKENBERGER RL, TROUP PJ, et al. Flecainide in the Treatment of Nonsustained Ventricular Tachycardia. Ann Intern Med. ;105:493–498. doi: 10.7326/0003-4819-105-4-493
Download citation file:
Published: Ann Intern Med. 1986;105(4):493-498.
Cardiology, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use